Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Wall Street Zen

Key Points

• Genmab A/S's stock rating was upgraded from "buy" to "strong-buy" by Wall Street Zen, signaling increased analyst confidence in the company's performance.
• The stock price has recently increased, reaching $29.07 with a market cap of $18.65 billion and positive earnings results showing earnings per share of $0.54, exceeding estimates.
• Despite the positive upgrades, Zacks Research lowered its rating from "strong-buy" to "hold," indicating mixed perceptions among analysts regarding the stock's future potential.

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Friday.

Several other analysts also recently weighed in on GMAB. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Tuesday. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. HC Wainwright increased their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, August 15th. Finally, Zacks Research cut shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.00.

Genmab A/S Stock Up 0.8%

Shares of Genmab A/S stock traded up $0.23 during trading hours on Friday, hitting $29.07. 1,038,006 shares of the company's stock traded hands, compared to its average volume of 1,390,938. The stock has a 50 day simple moving average of $24.96 and a 200-day simple moving average of $22.04. The company has a market cap of $18.65 billion, a PE ratio of 14.61, a PEG ratio of 1.68 and a beta of 0.93. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $29.51.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. Foresight Group Ltd Liability Partnership acquired a new position in shares of Genmab A/S during the first quarter worth approximately $954,000. Vident Advisory LLC acquired a new position in shares of Genmab A/S during the first quarter worth approximately $242,000. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock worth $656,000 after buying an additional 31,343 shares during the period. Fifth Third Bancorp boosted its position in shares of Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock worth $825,000 after buying an additional 6,015 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Genmab A/S by 19.8% during the first quarter. American Century Companies Inc. now owns 383,891 shares of the company's stock worth $7,517,000 after buying an additional 63,316 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.